EN
抗体药类似物
Research Grade Bamlanivimab
All
TD-VK565036_1.jpg
TD-VK565036_2.jpg
  • CatalogTD-VK565036
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsLY-3819253,LY-CoV555,LY3819253,CAS:2423943-37-5
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Bamlanivimab


Catalog No. TD-VK565036
Species reactivity SARS-CoV-2 (2019-nCoV)
Applications Research Grade Biosimilar
Host species Human
Isotype IgG1, kappa
Expression system Mammalian Cells
Clonality Monoclonal
Target Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, Spike protein S2, Spike protein S2', S, 2
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P0DTC2
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names LY-3819253,LY-CoV555,LY3819253,CAS:2423943-37-5
Background Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.
Note For research use only. Not for use in clinical or therapeutic applications.

 

TD-VK565036_1.jpg
Bioactivity
 
SEC-HPLC detection for Research Grade Bamlanivimab.
TD-VK565036_2.jpg
SDS-PAGE
 
SDS-PAGE for Research Grade Bamlanivimab.